摘要
目的探究并分析阿替普酶与尿激酶在急性心肌梗死患者中的应用效果。方法选取湖北省郧西县人民医院心内科2011年12月～2012年12月收治的175例急性心肌梗死患者为研究对象．运用随机数字表法将急性心肌梗死患者分为A组（75例）和B组（75例），A组患者接受尿激酶溶栓治疗，而B组患者则接受阿替普酶溶栓治疗，比较两组患者临床疗效。结果A组治疗总有效率为88．00％（66／75），B组治疗总有效率97．33％（73／75），两组患者治疗总有效率差异有统计学意义（P〈0．05），B组患者梗死后心绞痛（1．33％）和心律失常发生率（1．33％）明显低于A组，差异有统计学意义（P〈0．05），但是，两组患者心肌再梗死、心力衰竭、出院前死亡和出血发生率差异无统计学意义（P〉0．05）。结论阿替普酶治疗急性心肌梗死疗效确切，优于尿激酶，具有安全高效、主要终点事件发生率低、不良反应少等特点。
Objective To investigate the application effect of acute myocardial infarction patients by Atenolol or uroki- nase enzyme. Methods 175 acute myocardial infarction patients who were treated in the Department of Cardiology in Yunxi People＇s Hospital of Hubei Province from December 2011 to December 2012 were chosen as the research objects, they were divided into group A （75 cases） and group B （75 cases） by using a random number table, patients in group A were given urokinase thrombolysis treatment, but patients in group B were given Atenolol enzyme thrombolysis treatment, the clinical efficacy of acute myocardial infarction patients of two groups was evaluated. Results The~ total efficient rate was lower in group A than that in group B [88.00% （66/75） vs 97.33% （73/75）, P 〈 0.05], the post-infarc- tion angina pectoris （1.33%） and arrhythmia cordis rate （1.33%） in group B were lower those in group A （P 〈 0.05）, the differences of myocardial infarction again, heart failure, death before discharge and bleeding between the two groups were not significantly different （P 〉 0.05）. Conclusion Atenolol can obtaine satisfactory curative effect for acute myocar- dial infarction patients, and it is superior to urokinase enzyme, it has the features of safe, highly effective, low inci- dence of the primary end point events and less adverse reactions.
出处
《中国医药导报》
CAS
2014年第1期73-75,共3页
China Medical Herald
基金
江苏省卫生厅重点科研项目(编号K201104)
关键词
尿激酶
阿替普酶
急性心肌梗死
临床疗效
Urokinase enzyme
Atenolol
Acute myocardial infarction
Clinical efficacy
